Akums Launches Advanced Antibiotic Aztreonam-Avibactam to Tackle Drug-Resistant Infections

AKUMS Drugs & Pharmaceuticals Limited, India’s largest Contract Development and Manufacturing Organization (CDMO), has announced the launch of Aztreonam-Avibactam Injection, an advanced antibiotic therapy aimed at treating multidrug-resistant gram-negative bacterial infections. The therapy is designed for severe and life-threatening infections that show limited or no response to conventional antibiotics, particularly in intensive care settings.

“The rise of antimicrobial resistance has significantly reduced the effectiveness of conventional therapies,” said Sanjeev Jain, Managing Director, AKUMS. “Aztreonam-Avibactam represents an important advancement in addressing infections caused by highly resistant pathogens, especially where timely and effective intervention is critical.”

The growing need for such therapies is driven by the increasing prevalence of antimicrobial resistance (AMR) globally. Studies, including those published in The Lancet, estimate that AMR is associated with approximately 1.27 million deaths annually, underscoring the importance of continued innovation in treatment approaches. Gram-negative pathogens, particularly those producing metallo-beta-lactamases (MBLs) and carbapenemases, are among the more complex organisms to treat, often limiting the effectiveness of existing antibiotics. Projections indicate that this burden may continue to rise, reinforcing the need for targeted and effective solutions.

Multidrug-resistant infections, often referred to as “superbugs,” are commonly linked to conditions such as hospital-acquired pneumonia, complicated intra-abdominal infections, and severe urinary tract infections, posing significant challenges in clinical management. Aztreonam-Avibactam combines aztreonam, a monobactam antibiotic active against gram-negative bacteria, with avibactam, a beta-lactamase inhibitor that protects the antibiotic from enzymatic degradation. This dual-action mechanism enhances its effectiveness against resistant bacterial strains, enabling it to target pathogens that have developed resistance to multiple drug classes.

“Our Kotdwar facility reflects our commitment to delivering high-quality, globally compliant pharmaceutical solutions,” said Sandeep Jain, Managing Director, AKUMS. “With advanced infrastructure, specialized manufacturing environments, and robust quality systems, we ensure that complex therapies such as Aztreonam-Avibactam are developed and produced with the highest standards of safety, efficacy, and reliability. Our integrated capabilities enable us to consistently deliver such critical formulations in line with global quality benchmarks.”

The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand, designed to meet stringent global regulatory standards for complex sterile formulations. The development is further supported by the company’s dedicated Penem facility, a specialized infrastructure built to handle high-potency and advanced antibiotic formulations.

The therapy holds significant relevance in critical care settings, where delays or suboptimal treatment can have serious implications for patient outcomes. Clinical evidence indicates that the combination is well tolerated, with no major treatment-related adverse events reported, reinforcing its potential in managing complex, multidrug-resistant infections. Leveraging its strong R&D foundation, advanced manufacturing capabilities, and deep insight into evolving therapeutic demands, AKUMS continues to expand access to high-quality, globally compliant formulations. The company remains steadfast in its commitment to advancing critical therapies that enhance clinical outcomes and address pressing global healthcare challenges.